Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673567 | 0.97 | — | — | |
| SCHEMBL13460042 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL2112328 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL18978572 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL8281752 | 0.89 | SIGMAR1 (0.52) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL18978574 | 0.86 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL14185936 | 0.85 | — | — | |
| SCHEMBL10037464 | 0.83 | — | — | |
| SCHEMBL1581527 | 0.82 | — | — | |
| SCHEMBL7739788 | 0.82 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037398-B1 | METHOD FOR MANUFACTURING CHEMICAL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9982087-B2 | Method for producing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9982087-B2 | Method for producing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3037398-A1 | METHOD FOR MANUFACTURING CHEMICAL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| US-5990317-A | HISTAMINE H3 RECEPTOR ANTAGONIST FOR TREATING CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0837679-A4 | 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES | GLIATECH INC (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0837679-A1 | 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES | Gliatech, Inc. (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5652258-A | HISTAMINE ANTAGONISTS | GLIATECH, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1997020822-A1 | QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996038141-A1 | 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES | GLIATECH, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1994011378-A1 | ARYL THIOPYRANO[2,3,4-c,d]INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1994-05-26 | — | — | WO | disclosed |
| US-5314900-A | Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1994-05-24 | — | — | US | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | CYP1A2 288/4885SIGMAR1 93/4885EPHX1 1616/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | CYP1A2 288/4885SIGMAR1 93/4885EPHX1 1616/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | CYP1A2 288/4885SIGMAR1 93/4885EPHX1 1616/4885 |
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | NUDT1, OSGEP, CNOT9 | CYP1A2 785/4885SIGMAR1 4278/4885EPHX1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.